Meta-analysis of the association between NLRP1 polymorphisms and the susceptibility to vitiligo and associated autoimmune diseases
Metrics: PDF 385 views | HTML 880 views | ?
Juan Li1, Min Yan1, Yuan Zhang1, Chao Feng1, Huicong Wang1, Cuiyu Wang1 and Li Sun1
1Department of Dermatology, Central Hospital of Shengli Oil Field, Shandong, People’s Republic of China
Li Sun, email: email@example.com
Keywords: NLRP1, vitiligo, autoimmune disease, polymorphism, meta-analysis
Received: June 24, 2017 Accepted: September 04, 2017 Published: September 22, 2017
Genetic variants are linked to vitiligo and associated autoimmune diseases. We performed a meta-analysis to evaluate the effects of the rs12150220, rs2670660, and rs6502867 polymorphisms within the human NLR Family Pyrin Domain Containing 1 (NLRP1) gene. We initially identified 1,306 candidate articles through literature searches of Pubmed, WOS, Embase, CNKI, WANFANGI, Ovid, Scopus, and Cochrane in July 2017. After strict screening, we included 19 eligible case-control studies, and analyzed the data using Stata/SE 12.0 software. No difference between vitiligo cases and controls was detected for NLRP1 rs12150220, rs2670660, or rs6502867 under most genetic models [Passociation (P value of association test) > 0.05). With regard to vitiligo-associated autoimmune diseases, like Addison’s disease, type 1 diabetes, or systemic lupus erythematosus, a decreased risk was detected for rs12150220 in the Caucasian subgroup under all models [Passociation < 0.05, odds ratio (OR) < 1]. No relationships were observed for other polymorphisms, including rs2670660, rs6502867, and the “A-A, G-T, G-A, A-T” haplotypes of rs2670660/rs12150220 (Passociation > 0.05). This meta-analysis demonstrates that within the Caucasian population, the NLRP1 rs12150220 polymorphism may correlate with a decreased risk of vitiligo-associated autoimmune diseases, especially autoimmune Addison’s disease, type 1 diabetes, or systemic lupus erythematosus.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.